AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07038124 or vehicle

First Posted Date: 2021-04-28

Last Posted Date: 2024-01-25

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04863417

Locations: 🇯🇵
P-one clinic, Keikokai medical corporation, Hachioji, Tokyo, Japan

Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Crizotinib

First Posted Date: 2021-04-23

Last Posted Date: 2022-01-20

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT04856293

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Study in Healthy Adults Evaluating PF-07202954

Phase 1

Completed

Conditions: Non-Alcoholic Fatty Liver Disease
Liver Fibrosis

Interventions: Drug: PF-07202954 Single Dose
Drug: PF-07202954 Repeat Dose
Drug: Placebo

First Posted Date: 2021-04-23

Last Posted Date: 2021-11-15

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04857437

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California

Recruiting

Conditions: COVID-19

Interventions: Biological: XBB.1.5-adapted vaccinated
Biological: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine
Biological: BNT162b2 BA.4/5 bivalent

First Posted Date: 2021-04-19

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 999

Registration Number: NCT04848584

Locations: 🇺🇸
Kaiser Permanente Southern California, Pasadena, California, United States

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention

Phase 2

Terminated

Conditions: Microvascular Obstruction

Interventions: Drug: Temanogrel
Drug: Placebo

First Posted Date: 2021-04-19

Last Posted Date: 2023-12-12

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT04848220

Locations: 🇬🇧
East and North Hertfordshire NHS Trust Lister Hospital, Stevenage, United Kingdom
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇦🇺
Concord Repatriation General Hospital, Concord, New South Wales, Australia

and more 9 locations

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Phase 3

Completed

Conditions: Chronic Myelomonocytic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Glasdegib
Drug: Azacitidine

First Posted Date: 2021-04-13

Last Posted Date: 2023-12-18

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT04842604

Locations: 🇦🇹
Landeskrankenhaus Salzburg, Universitatsklinik fur Innere Medizin III der PMU, Salzburg, Austria
🇭🇺
Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika, Hematologia Tanszek, Debrecen, Hungary
🇦🇹
Uniklinikum Salzburg, Landeskrankenhaus Salzburg, Salzburg, Austria

and more 15 locations

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: PF-06882961 + PF-06865571
Drug: PF-06882961 followed by PF-06882961/PF-06865571
Drug: PF-06882961/PF-06865571 followed by PF-06882961

First Posted Date: 2021-04-09

Last Posted Date: 2023-08-21

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT04839393

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States

A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: Marstacimab PFP
Drug: Marstacimab PFS

First Posted Date: 2021-04-05

Last Posted Date: 2022-07-11

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT04832139

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients

Phase 4

Completed

Conditions: Transthyretin Amyloid Polyneuropathy (ATTR-PN)

Interventions: Drug: tafamidis meglumine

First Posted Date: 2021-04-02

Last Posted Date: 2024-03-12

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT04828993

Locations: 🇨🇳
Peking union hospital of Chinese academy of medical sciences, Beijing, China
🇨🇳
Tiantan Hospital Capital Medical University, Beijing, China
🇨🇳
Peking University First Hospital, Beijing, Beijing, China

and more 5 locations

Monitoring Activity And Gait In Children

Completed

Conditions: Child, Preschool
Adolescent
Child

Interventions: Device: Panoramic Bracelet and GENEActiv

First Posted Date: 2021-04-01

Last Posted Date: 2025-01-22

Lead Sponsor: Pfizer

Target Recruit Count: 87

Registration Number: NCT04823650

Locations: 🇺🇸
Pfizer Innovation Research, PfIRe, Lab, Cambridge, Massachusetts, United States

Home Terms & Conditions Privacy Policy